Enzyme experiment extended survival in pancreatic cancer

Share this article:

Adding an enzyme to the standard chemotherapeutic regimen for pancreatic cancer nearly doubled overall survival time in a mouse model.

Pancreatic ductal adenocarcinomas are highly resistant to chemotherapy, due in part to a unique biologic barrier the tumor builds around itself. In the current study, the research team identified hyaluronan, or hyaluronic acid (HA), as the primary matrix component of these barriers and showed that systemic administration of an enzyme known as PEGPH20 could degrade HA in the tumor barrier.

Working with a genetically engineered mouse model of pancreatic ductal adenocarcinoma, the investigators combined the PEGPH20 enzyme with gemcitabine, the current standard chemotherapeutic agent employed to combat such tumors. Use of the enzyme set off a chain of biologic events that ultimately broke down the barrier and allowed high concentrations of chemotherapy to reach the tumor and spread throughout the diseased tissue (Cancer Cell. 2012;21[3]:418-429). The result was a 70% increase in overall survival after the start of treatment, from 55 days to 92 days.

Early clinical trials in humans are under way in the United States and in Russia; visit http://clinicaltrials.gov/show/NCT01453153 for eligibility and enrollment information.

Share this article:
You must be a registered member of ONA to post a comment.
close

Next Article in Web Exclusives

Sign Up for Free e-newsletters


What is this?

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Some aggressive cancers may respond to anti-inflammatory drugs

New research raises the prospect that some cancer patients with aggressive tumors may benefit from a class of anti-inflammatory drugs currently used to treat rheumatoid arthritis.

Single gene determines if rare lymphatic system cancer is aggressive

For a rare form of cancer called thymoma, researchers have discovered a single gene defining the difference between a fast-growing tumor requiring aggressive treatment and a slow-growing tumor that does not require extensive therapy.

More than 40 melanoma-specific genes determine disease aggressiveness

Researchers have discovered more than 40 genes that predict the level of aggressiveness of melanoma and that distinguish it from other cancers with a poor prognosis.